This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moussa, O. Articles by Watson, D. K. Search for Related Content PubMed PubMed Citation Articles by Moussa, O. Articles by Watson, D. K.

Prognostic and Functional Significance of Thromboxane Synthase Gene Overexpression in Invasive Bladder Cancer

Departments of ¹ Pathology and Laboratory Medicine, ² Biochemistry and Molecular Biology, ³ Urology, ⁴ Pharmacology and Medicine, and ⁵ Biostatistics, Bioinformatics, and Epidemiology and ⁶ Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina and ⁷ Urology and Nephrology Center, Mansoura University, Mansoura, Egypt

Requests for reprints: Dennis K. Watson, Hollings Cancer Center, Medical University of South Carolina, Room 332, 86 Jonathan Lucas Street, Charleston, SC 29425. Phone: 843-792-3962; Fax: 843-792-3940; E-mail: watsondk{at}musc.edu.

Thromboxane synthase (TXAS) is one of the enzymes downstream from cyclooxygenase-2 and catalyzes the synthesis of thromboxane A₂ (TXA₂). TXAS was among the genes we identified based on its overexpression in invasive bladder tumors. TXAS is overexpressed in common forms of bladder tumors: 69 of 97 (71.1%) transitional cell carcinoma (TCC), 38 of 53 (71.6%) squamous cell carcinoma, and 5 of 11 (45.5%) adenocarcinoma relative to nontumor tissue. Overall, 112 of 161 (69.5%) invasive tumors exhibited elevated expression. Significantly, patients with tumors having >4-fold levels of TXAS expression showed significant statistical evidence of lower overall survival expressed by the estimated hazard ratio of 2.74 with P = 0.009 in Cox's regression analysis. TXAS mRNA expression was found to be an independent prognostic marker for patients with bladder cancer. Treatment of bladder cancer cell lines (T24 and TCC-SUP) with TXAS inhibitors and TXA₂ (TP) receptor antagonists reduced cell growth, migration, and invasion, whereas TP agonists stimulated cell migration and invasion. The positive correlation between elevated TXAS expression and shorter patient survival supports a potential role for TXAS-regulated pathways in tumor invasion and metastases and suggests that modulation of the TXAS pathway may offer a novel therapeutic approach. (Cancer Res 2005; 65(24): 11581-7)

This article has been cited by other articles:

				O. Moussa, A. W. Ashton, M. Fraig, E. Garrett-Mayer, M. A. Ghoneim, P. V. Halushka, and D. K. Watson Novel Role of Thromboxane Receptors {beta} Isoform in Bladder Cancer Pathogenesis Cancer Res., June 1, 2008; 68(11): 4097 - 4104. [Abstract] [Full Text] [PDF]

				D. J. Kerr, J. A. Dunn, M. J. Langman, J. L. Smith, R. S.J. Midgley, A. Stanley, J. C. Stokes, P. Julier, C. Iveson, R. Duvvuri, et al. Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer N. Engl. J. Med., July 26, 2007; 357(4): 360 - 369. [Abstract] [Full Text] [PDF]

				X. de Leval, T. Dassesse, J.-M. Dogne, D. Waltregny, A. Bellahcene, V. Benoit, B. Pirotte, and V. Castronovo Evaluation of Original Dual Thromboxane A2 Modulators as Antiangiogenic Agents J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1057 - 1067. [Abstract] [Full Text] [PDF]